In addition, a transcriptional synergy between estrogen receptor and NF-κB has been described, which results in a gene signature that correlates with chemo-resistance and poor patient outcome in a subset of ER+ breast cancer [15], [16]. Here, NFKB1 is linked to breast carcinoma.